Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...

Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...

Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...

Neoadjuvant immunotherapy offers a survival benefit in specific subtypes of patients but seems to offer no benefit in the ...

Among 64 patients who received immune checkpoint inhibitors, 78% had downstaging of their liver tumor to within Milan ...

Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, ...

Through a first-of-its-kind report, the Canadian Mental Health Association (CMHA) is providing an in-depth look at the mental health system in Canada?with all its cracks and failings?and how people ...

The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...

As AI-generated content floods the internet, often lacking depth and real-world application, SmartLifeSkills.ai aims to transform this landscape. The platform leverages proprietary AI to deliver a ...

Keytruda (pembrolizumab) brings cancer cells out from hiding. It has been approved for treating several cancers on the NHS, ...

Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be ...